Neoadjuvant90Yttrium peptide receptor radionuclide therapy for advanced rectal neuroendocrine tumour: a case report

2014 ◽  
Vol 87 (1-2) ◽  
pp. 92-93 ◽  
Author(s):  
Jennifer Ryan ◽  
Timothy Akhurst ◽  
A. Craig Lynch ◽  
Michael Michael ◽  
Alexander G. Heriot
Keyword(s):  
Case Report ◽  
Radionuclide Therapy ◽  
Neuroendocrine Tumour ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor

scholarly journals Paraganglioma of the thyroid gland: A case report

2014 ◽  
Vol 71 (9) ◽  
pp. 875-878 ◽  
Author(s):  
Aleksandar Filipovic ◽  
Ljiljana Vuckovic ◽  
Ljubica Pejakov
Keyword(s):  
Case Report ◽  
Thyroid Gland ◽  
Ct Scan ◽  
Neuroendocrine Tumor ◽  
Radionuclide Therapy ◽  
Neuron Specific Enolase ◽  
Peptide Receptor Radionuclide Therapy ◽  
Left Lobe ◽  
Whole Body ◽  
Peptide Receptor

Introduction. Thyroid paraganglioma is a very rare malignant neuroendocrine tumor. Immunohistochemical features of thyroid paraganglioma are helpful for the diagnosis. Case report. A 69-year-old female came to hospital with the presence of a growing thyroid nodule of the left lobe. Ultrasonic neck examination showed 5 cm hypoechoic nodule in the left thyroid lobe. Thyroid scintigraphy showed a big cold nodule in the left lobe. Computed tomography (CT) scan showed left lobe thyroid tumor with tracheal deviation on the right site. Extended total thyroidectomy was done. Intraoperative consultation with the pathologist confirmed thyroid cancer. The pathologist diagnosed thyroid paraganglioma on the base of immuohistochemical investigation. This thyroid paraganglioma was positive for neuron-specific enolase, chomogranin A, synaptophysin, and S-100 protein highlighted the sustentacular cells. Tumor cells were nega-tive for thyroglobulin, epithelial membrane antigen, cytokeratin, calcitonin, and carcinoembryonic. After the surgery the patient was treated with chemotherapy, peptide receptor radionuclide therapy, and permanent TSH suppressive therapy. The patient was followed with measurements of thyroid hormone and serum neuron-specific enolase, chromogranin A level, every 6 months. Gastroscopy, colonoscopy, chest and abdomen CT scan as well as further tests (chest x-ray, ultrasound of the neck, and whole body octreotide scintigraphy) were done. No primary neuroendocrine tumor in digestive sistem or in the chest was found. After more than 3 years the patient has no evidence of the recurrent disease. Conclusion. Radical resection of thyroid paraganglioma, followed by chemotherapy and peptide receptor radionuclide therapy, should be considered the treatment of choice in patients with thyroid gland paraganglioma.

scholarly journals Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient’s therapy course

PLoS ONE ◽  
2021 ◽  
Vol 16 (11) ◽  
pp. e0260073
Author(s):  
Daphne M. V. de Vries–Huizing ◽  
Michelle W. J. Versleijen ◽  
Michiel Sinaasappel ◽  
Iris Walraven ◽  
Martine M. Geluk–Jonker ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Selection Criteria ◽  
Progressive Disease ◽  
Neuroendocrine Tumour ◽  
Somatostatin Receptor ◽  
Peptide Receptor Radionuclide Therapy ◽  
Tumour Volume ◽  
Clinical Impact ◽  
Peptide Receptor ◽  
Grade 3

Background Mainly severe (CTCAE grade 3–4) haematotoxicity during peptide receptor radionuclide therapy (PRRT) is reported in literature due to major clinical impact, however moderate (CTCAE grade 2) haematotoxicity is common and could affect therapy management. The aim of this study was to evaluate the haematotoxicity course during PRRT and to compare baseline parameters between haematotoxicity grades. Methods In this retrospective study, 100 patients with a neuroendocrine tumour treated with PRRT were included. Patients were treated with an aimed number of four cycles with 7.4 GBq [177Lu]Lu-DOTA-TATE administered every 10 weeks. Haematological assessment was performed at baseline and frequently up to 10 weeks after the fourth cycle. The lowest haematological value was graded according to CTCAE v5.0, and patients were classified using the highest observed grade. Differences in baseline parameters, including [68Ga]Ga-DOTA-TATE positive tumour volume, were evaluated between CTCAE grades. Results Four cycles were completed by 86/100 of patients, 4/100 patients discontinued due to haematotoxicity, and 10/100 patients due to progressive disease. The treatment course was adjusted due to haematotoxicity in 24/100 patients, including postponed next cycle (n = 17), reduced administered activity (n = 13), and both adjustments (n = 10). The most observed haematotoxicity grade was grade 0–1 in 54/100 patients, grade 2 in 38/100 and grade 3–4 in 8/100. Significant differences in baseline leucocyte, neutrophil and platelet counts were observed between grade 0–1 and grade 2. However, the correlation between baseline and lowest observed values was poor to moderate. No differences between haematotoxicity grades and baseline parameters or somatostatin receptor positive tumour volume was observed. Conclusions The incidence of severe haematotoxicity was low with extensive screening and monitoring. The vast majority of patients (96/100) was not restricted in treatment continuation by haematotoxicity; therefore, our selection criteria appeared appropriate for safe PRRT treatment. Baseline parameters showed limited correlation with the degree of decline in haematological values.

Efficacy of Lutetium-Peptide Receptor Radionuclide Therapy in Inducing Prolonged Tumour Regression in Small-Bowel Neuroendocrine Tumours: A Case of Favourable Response to Retreatment after Initial Objective Response

2021 ◽  
pp. 1-4
Author(s):  
Maria Rinzivillo ◽  
Daniela Prosperi ◽  
Mirco Bartolomei ◽  
Stefano Panareo ◽  
Elsa Iannicelli ◽  
...  
Keyword(s):  
Case Report ◽  
Small Bowel ◽  
Radionuclide Therapy ◽  
Neuroendocrine Tumours ◽  
Therapeutic Option ◽  
Tumour Response ◽  
Peptide Receptor Radionuclide Therapy ◽  
Phase Iii ◽  
Peptide Receptor ◽  
Initial Objective

<b><i>Introduction:</i></b> The efficacy of 177Lu-Dotatate was shown in the NETTER-1 trial, an international, open-label, multicentre phase III clinical trial that evaluated the safety and efficacy of 177Lu-Dotatate in patients with well-differentiated, advanced midgut neuroendocrine tumours (NETs) with evidence of disease progression. Recently, retreatment with peptide receptor radionuclide therapy (PRRT) has been proposed as a valid therapeutic option in patients without other effective options who had responded to initial PRRT; however, data on this therapeutic option are still inadequate. <b><i>Case Report:</i></b> In this report, we present the case of a patient who achieved a delayed complete radiological response after initial 177Lu-Dotatate treatment and who had a complete tumour response with PRRT retreatment 5 years later. <b><i>Conclusions:</i></b> This case report shows that, although rare, a complete, prolonged tumour response may occur in patients with advanced small-bowel NETs receiving PRRT. Retreatment with PRRT may be a valid option in cases of subsequent disease recurrence.

scholarly journals P06.04 * PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) WITH 90Y-DOTATOC TARGETING OF RECURRENT ATYPICAL MENINGIOMA: A CASE REPORT

2014 ◽  
Vol 16 (suppl 2) ◽  
pp. ii45-ii45
Author(s):  
S. Iglseder ◽  
M. Nowosielski ◽  
A. Muigg ◽  
G. Stockhammer ◽  
C. Freyschlag ◽  
...  
Keyword(s):  
Case Report ◽  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Atypical Meningioma ◽  
Peptide Receptor
Sign in / Sign up

Export Citation Format

Share Document